The “genetics of mental disorders” story told in Kolker's "Hidden Valley Road" involves omission and misrepresentation of genetic research.
From Medium/Rev. Sheri Heller, LCSW: The 'symptom bearer' or 'identified patient' is the scapegoat who carries the evidence of the familial dysfunction.
When people seeking help are relegated to “the Other,” how can they ever form a “therapeutic alliance”? Without collaboration, treatment devolves into coercion and oppression. We must change our language and relationships so new narratives can be born.
New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.
Long-term exposure to prolactin-increasing antipsychotics increases the odds of developing breast cancer.
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.
Research finds that social cognition and emotional processing abilities can be disrupted by psychiatric drugs.
Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.
Researchers question the long-term use of antipsychotics and suggest increased research and investment in psychosocial interventions.
This article is written for the loving supporter or social worker. My hope is that it will help you gain strategies for how to handle the relationship with someone experiencing psychosis.
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.
Ayurdhi Dhar interviews Tanya Luhrmann about cultural differences in voice-hearing, diagnosis and damaged identities, and conflicts in psychiatry.
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.
It is uncomfortably difficult to look at Phoebe Sparrow Wagner’s art. That much is intentional. She shakes up the viewer’s sense of wellbeing and security so that they can better identify with the plight of the mental patient.
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
If the cultural and socioeconomic structures of society had, from the beginning, allowed me to function, and even thrive, I undoubtedly never would have felt a need for antidepressants and “therapy.”
If I disclose my situation, then professionally, the attributional association of “the therapist with schizophrenia“ will necessarily and inevitably follow. But this is not who I am. Rather, I am a therapist with a private medical issue and I prefer to maintain its confidentiality—no further justification needed.